Last reviewed · How we verify
The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies
CD19 is expressed in most B malignant tumors, especially in the former B cells ALL. This makes CD19 a natural target of immunotherapy. In terms of safety, the lack of B cells caused by CD19 targeted therapy will not cause life-threatening side effects (of course, Ig supplementation is necessary in the long-term B cell inhibition therapy). Moreover, the number of B cells can be restored after removing anti-CD19 treatment measures (such as anti-CD19 CART cells). In addition, CD19 has been chosen as the target of B-ALL therapy for the following reasons: ① as the BCR signal "amplifier", CD19 plays a role in PAX-5-mediated tumor formation; ② by activating MYC (as the oncogene controlled by PAX-5, C-MYC plays a key role in promoting the malignant proliferation of B cells), CD19 can cause B-ALL formation. Based on the above reasons, CD19 has become an ideal target in the treatment of B-cell cancer.
Details
| Lead sponsor | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | UNKNOWN |
| Enrolment | 10 |
| Start date | Tue Jan 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Jan 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- B Acute Lymphoblastic Leukemia
- Mantle Cell Lymphoma
- Follicular Lymphoma
Interventions
- CD19-CART
Countries
China